Search bioRxiv⌕ Search

Biology subjects

Platz, E. A.

Publications and source records attributed to Platz, E. A..

2 recordsLinked to original sources

Photochemical pre-bleaching of formalin-fixed archival prostate tissues significantly reduces autofluorescence to facilitate multiplex immunofluorescence staining

The characterization of tissues using multiple different primary antibodies detected by secondary antibodies, each possessing a different colored fluorophore (multiplex immunofluorescence), is a powerful technique but often impaired by endogenous autofluorescence present in the specimen. Our current research involves the use of multiplex immunofluorescence to identify specific cell phenotypes within the tumor microenvironment in archival formalin-fixed paraffin-embedded human prostate cancer tissue specimens. These specimens frequently possess high levels of autofluorescence, in part due to the biological age of the tissues and long storage times. This autofluorescence interferes with and, in the worst cases, completely obscures the desired immunofluorescent signals, thus impeding analyses by decreasing signal-to-noise. Here, we demonstrate that a recently published protocol for photochemical bleaching significantly decreases autofluorescence (80% average decrease of the brightest autofluorescent signals), across the visible spectrum, in fixed, archival prostate tissue specimens from aged men, that have been sectioned onto glass slides and stored for several months. Importantly, the method is compatible with subsequent immunofluorescence staining and yields markedly improved signal-to-noise. Inclusion of this method should facilitate studies employing multiplex immunofluorescence in sections cut from archival fixed human prostate tissues.

pathology↗

A combined proteomics and Mendelian randomization approach to investigate the effects of aspirin-targeted proteins on colorectal cancer

BackgroundEvidence for aspirins chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk. MethodsHuman colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labelling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (N=3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (N=31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was performed using eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases and 65,160 controls). ResultsAltered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2 and ARFIP2 expression and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR:1.08, 95% CI:1.03-1.13, OR:3.33, 95% CI:2.46-4.50 and OR:1.15, 95% CI:1.02-1.29, respectively). ConclusionMCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation indicating a possible role in aspirins reduction of metastasis. ImpactOur approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.

cancer biology↗